Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma

摘要: We performed a phase II trial of docetaxel in combination with capecitabine to evaluate the antitumor response, toxicity, and survival pre-treated patients advanced esophageal squamous cell carcinoma. Patients carcinoma who had failed first-line chemotherapy cisplatin 5-fluorouracil were enrolled this study. Treatment consisted oral (825 mg/m2 twice daily on days 1–14) plus 1-h intravenous (60 mg/m2 day 1) every 3 weeks for up 6 cycles. Between June 2008 August 2011, thirty eligible median age 58 years (range 38–68 years) enrolled. received three cycles treatment 1–6). The follow-up was 15.4 months 1.0–31.5 months). Intent-to-treat efficacy analysis demonstrated an overall response rate 23.3 % (0 complete 7 partial response) stable disease 43.4 % (n = 13). time progression 3.0 months (95 % CI 1.9–4.1 months). 8.3 months 6.8–9.8 months). Severe adverse events (grade 3/4) reported as follows: neutropenia (33.3 %, n = 10, including febrile 6.7 %, n = 2), anemia (16.7 %, n = 5), thrombocytopenia (10 %, n = 3), hand–foot syndrome (13.3 %, n = 4), fatigue n = 3). Docetaxel manageable event profile promising activity advance second-line treatment.